Trial Search Results
Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)
The study is examining if an over-the-counter device (Theravent) worn while sleeping can reduce acute mountain sickness upon awakening in a high altitude trekking population.
Stanford is currently not accepting patients for this trial.
Collaborator: University of Utah
- Device: Theravent
- Device: Control
- ages 18-65
- Lake Louise Score (LLS) of < 3
- Have not taken NSAIDs, acetazolamide, or corticosteroids in the prior week
- Have not traveled above 4200 m in the prior week.
- First night in Pheriche or Dingboche
- Unable to read the consent form
- Taken NSAIDs, acetazolamide, or corticosteroids in the week prior to study enrollment.
- Hazardous medical conditions which precludes the ability to tolerate the experimental
- Pregnancy or suspected pregnancy.
- Participants who are younger than 18 years of age and more than 65.
- Travel to or above 4200m in the preceding week.
- Diagnosis of AMS upon enrollment (LLS ≥3 with symptoms of headache)
- Previously diagnosed obstructive sleep apnea
- Current symptoms of nasal congestion, rhinorrhea, sinusitis, upper respiratory
infection, asthma, COPD exacerbation, pneumonia, bronchitis, or other disease of the
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study